These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 33570712)

  • 1. Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype.
    Ciardiello D; Blauensteiner B; Matrone N; Belli V; Mohr T; Vitiello PP; Martini G; Poliero L; Cardone C; Napolitano S; De Falco V; Giunta EF; Ciaramella V; Corte CD; Barra G; Selvaggi F; Franco R; Marino FZ; Cuomo A; Morgillo F; Troiani T; Sibilia M; Ciardiello F; Martinelli E
    Med Oncol; 2021 Feb; 38(3):24. PubMed ID: 33570712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib.
    Giles KM; Kalinowski FC; Candy PA; Epis MR; Zhang PM; Redfern AD; Stuart LM; Goodall GJ; Leedman PJ
    Mol Cancer Ther; 2013 Nov; 12(11):2541-58. PubMed ID: 24026012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AXL targeting reduces fibrosis development in experimental unilateral ureteral obstruction.
    Landolt L; Furriol J; Babickova J; Ahmed L; Eikrem Ø; Skogstrand T; Scherer A; Suliman S; Leh S; Lorens JB; Gausdal G; Marti HP; Osman T
    Physiol Rep; 2019 May; 7(10):e14091. PubMed ID: 31134766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer.
    Dunne PD; McArt DG; Blayney JK; Kalimutho M; Greer S; Wang T; Srivastava S; Ong CW; Arthur K; Loughrey M; Redmond K; Longley DB; Salto-Tellez M; Johnston PG; Van Schaeybroeck S
    Clin Cancer Res; 2014 Jan; 20(1):164-75. PubMed ID: 24170546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma.
    Hector A; Montgomery EA; Karikari C; Canto M; Dunbar KB; Wang JS; Feldmann G; Hong SM; Haffner MC; Meeker AK; Holland SJ; Yu J; Heckrodt TJ; Zhang J; Ding P; Goff D; Singh R; Roa JC; Marimuthu A; Riggins GJ; Eshleman JR; Nelkin BD; Pandey A; Maitra A
    Cancer Biol Ther; 2010 Nov; 10(10):1009-18. PubMed ID: 20818175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-Cell Proteomic Profiling Identifies Combined AXL and JAK1 Inhibition as a Novel Therapeutic Strategy for Lung Cancer.
    Taverna JA; Hung CN; DeArmond DT; Chen M; Lin CL; Osmulski PA; Gaczynska ME; Wang CM; Lucio ND; Chou CW; Chen CL; Nazarullah A; Lampkin SR; Qiu L; Bearss DJ; Warner S; Whatcott CJ; Mouritsen L; Wade M; Weitman S; Mesa RA; Kirma NB; Chao WT; Huang TH
    Cancer Res; 2020 Apr; 80(7):1551-1563. PubMed ID: 31992541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual Inhibition of MEK and AXL Targets Tumor Cell Heterogeneity and Prevents Resistant Outgrowth Mediated by the Epithelial-to-Mesenchymal Transition in NSCLC.
    Konen JM; Rodriguez BL; Padhye A; Ochieng JK; Gibson L; Diao L; Fowlkes NW; Fradette JJ; Peng DH; Cardnell RJ; Kovacs JJ; Wang J; Byers LA; Gibbons DL
    Cancer Res; 2021 Mar; 81(5):1398-1412. PubMed ID: 33402388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer.
    Lin JZ; Wang ZJ; De W; Zheng M; Xu WZ; Wu HF; Armstrong A; Zhu JG
    Oncotarget; 2017 Jun; 8(25):41064-41077. PubMed ID: 28455956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer.
    Antony J; Tan TZ; Kelly Z; Low J; Choolani M; Recchi C; Gabra H; Thiery JP; Huang RY
    Sci Signal; 2016 Oct; 9(448):ra97. PubMed ID: 27703030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AXL Mediates Esophageal Adenocarcinoma Cell Invasion through Regulation of Extracellular Acidification and Lysosome Trafficking.
    Maacha S; Hong J; von Lersner A; Zijlstra A; Belkhiri A
    Neoplasia; 2018 Oct; 20(10):1008-1022. PubMed ID: 30189359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AXL receptor as an emerging molecular target in colorectal cancer.
    De Rosa L; Di Stasi R; Fusco V; D'Andrea LD
    Drug Discov Today; 2024 Jun; 29(6):104005. PubMed ID: 38685399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma.
    Meel MH; de Gooijer MC; Metselaar DS; Sewing ACP; Zwaan K; Waranecki P; Breur M; Buil LCM; Lagerweij T; Wedekind LE; Twisk JWR; Koster J; Hashizume R; Raabe EH; Montero Carcaboso Á; Bugiani M; Phoenix TN; van Tellingen O; van Vuurden DG; Kaspers GJL; Hulleman E
    Clin Cancer Res; 2020 Jul; 26(13):3319-3332. PubMed ID: 32165429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of Axl improves the targeted therapy against ALK-mutated neuroblastoma.
    Xu F; Li H; Sun Y
    Biochem Biophys Res Commun; 2014 Nov; 454(4):566-71. PubMed ID: 25450694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Axl kinase drives immune checkpoint and chemokine signalling pathways in lung adenocarcinomas.
    Tsukita Y; Fujino N; Miyauchi E; Saito R; Fujishima F; Itakura K; Kyogoku Y; Okutomo K; Yamada M; Okazaki T; Sugiura H; Inoue A; Okada Y; Ichinose M
    Mol Cancer; 2019 Feb; 18(1):24. PubMed ID: 30744655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small molecule inhibition of Axl receptor tyrosine kinase potently suppresses multiple malignant properties of glioma cells.
    Vouri M; An Q; Birt M; Pilkington GJ; Hafizi S
    Oncotarget; 2015 Jun; 6(18):16183-97. PubMed ID: 25980499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long noncoding RNA H19 regulates HIF-1α/AXL signaling through inhibiting miR-20b-5p in endometrial cancer.
    Zhu H; Jin YM; Lyu XM; Fan LM; Wu F
    Cell Cycle; 2019 Oct; 18(19):2454-2464. PubMed ID: 31411527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous Cancer.
    Palisoul ML; Quinn JM; Schepers E; Hagemann IS; Guo L; Reger K; Hagemann AR; McCourt CK; Thaker PH; Powell MA; Mutch DG; Fuh KC
    Mol Cancer Ther; 2017 Dec; 16(12):2881-2891. PubMed ID: 28904132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implication of the Receptor Tyrosine Kinase AXL in Head and Neck Cancer Progression.
    von Mässenhausen A; Brägelmann J; Billig H; Thewes B; Queisser A; Vogel W; Kristiansen G; Schröck A; Bootz F; Brossart P; Kirfel J; Perner S
    Int J Mol Sci; 2016 Dec; 18(1):. PubMed ID: 28025482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibiting the GAS6/AXL axis suppresses tumor progression by blocking the interaction between cancer-associated fibroblasts and cancer cells in gastric carcinoma.
    Bae CA; Ham IH; Oh HJ; Lee D; Woo J; Son SY; Yoon JH; Lorens JB; Brekken RA; Kim TM; Han SU; Park WS; Hur H
    Gastric Cancer; 2020 Sep; 23(5):824-836. PubMed ID: 32239298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.
    Byers LA; Diao L; Wang J; Saintigny P; Girard L; Peyton M; Shen L; Fan Y; Giri U; Tumula PK; Nilsson MB; Gudikote J; Tran H; Cardnell RJ; Bearss DJ; Warner SL; Foulks JM; Kanner SB; Gandhi V; Krett N; Rosen ST; Kim ES; Herbst RS; Blumenschein GR; Lee JJ; Lippman SM; Ang KK; Mills GB; Hong WK; Weinstein JN; Wistuba II; Coombes KR; Minna JD; Heymach JV
    Clin Cancer Res; 2013 Jan; 19(1):279-90. PubMed ID: 23091115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.